Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52

HOS-109010 · Präparat HOS-093083

For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions). Patients should be closely monitored for signs related to venetoclax toxicities. Anticoagulants Warfarin Warfarin: It is recommended that INR Concentrations may be affected (international normalised ratio) be when co-administered with monitored. lopinavir/ritonavir due to CYP2C9 induction. Rivaroxaban Rivaroxaban: Co-administration of rivaroxaban and AUC: ↑ 153% Kaletra may increase rivaroxaban (Ritonavir 600 mg twice Cmax: ↑ 55% exposure which may increase the risk daily) Due to CYP3A and P-gp of bleeding. inhibition by lopinavir/ritonavir. The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Kaletra (see section 4.4). Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to Pgp inhibition by considered when a DOAC lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with Kaletra. moderately decreased due to Phenytoin levels should be monitored CYP2C9 and CYP2C19 induction when co-administering with Kaletra. by lopinavir/ritonavir. When co-administered with phenytoin, an increase of Kaletra Lopinavir: dosage may be envisaged. Dose Concentrations are decreased due adjustment has not been evaluated in to CYP3A induction by clinical practice. phenytoin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): venetoclax (HOS-086143) rivaroxaban (HOS-086236) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531) warfarin (HOS-085950)